Updated prevalence of genotypic resistance among HIV‐1 positive patients naïve to antiretroviral therapy: a single center analysis
暂无分享,去创建一个
Carlo Torti | C. Torti | I. Izzo | N. Manca | G. Carosi | E. Quiros-Roldan | G. Lapadula | Giampiero Carosi | Nino Manca | Eugenia Quiros-Roldan | G. Cologni | G. Paraninfo | F. Castelnuovo | Giuseppe Lapadula | Giuliana Cologni | Franco Gargiulo | F. Gargiulo | Ilaria Izzo | Giuseppe Paraninfo | Filippo Castelnuovo | Francesca Ceresoli | F. Ceresoli
[1] A. Geretti. Epidemiology of antiretroviral drug resistance in drug-naïve persons , 2007, Current opinion in infectious diseases.
[2] R. Kaiser,et al. Primary HIV Drug Resistance and Efficacy of First-Line Antiretroviral Therapy Guided by Resistance Testing , 2006, Journal of acquired immune deficiency syndromes.
[3] C. Torti,et al. Prevalence of drug resistance and newly recognised treatment-related substitutions in the HIV-1 reverse transcriptase and protease genes from HIV-positive patients naïve for anti-retrovirals. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[4] M. Chesney,et al. Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection , 2007, AIDS.
[5] Elizabeth Connick,et al. Antiretroviral-drug resistance among patients recently infected with HIV. , 2002, The New England journal of medicine.
[6] Klaus Korn,et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. , 2005, The Journal of infectious diseases.
[7] Soo-Yon Rhee,et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance , 2007, AIDS.
[8] Simon D W Frost,et al. Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission. , 2007, The Journal of infectious diseases.
[9] L. Bacheler,et al. Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors , 2005, AIDS.
[10] Alessandro Cozzi-Lepri,et al. Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy , 2004, AIDS.
[11] S. Little. Transmission and Prevalence of HIV Resistance among Treatment-Naive Subjects , 2000, Antiviral therapy.
[12] A. Phillips,et al. Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. , 2007, The Journal of antimicrobial chemotherapy.
[13] D. Pillay,et al. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study , 2005, BMJ : British Medical Journal.
[14] R. Kaiser,et al. Trends of prevalence of primary HIV drug resistance in Germany. , 2007, The Journal of antimicrobial chemotherapy.
[15] A. Kamarulzaman,et al. Short communication: low prevalence of genotypic drug resistance mutations among antiretroviral-naive HIV type 1 patients in Malaysia. , 2006, AIDS research and human retroviruses.
[16] Jonathan M. Schapiro,et al. Genotypic Changes in Human Immunodeficiency Virus Type 1 Protease Associated with Reduced Susceptibility and Virologic Response to the Protease Inhibitor Tipranavir , 2006, Journal of Virology.
[17] H. Sørensen,et al. Declining Prevalence of HIV-Infected Individuals at Risk of Transmitting Drug-Resistant HIV in Denmark during 1997–2004 , 2005, Antiviral therapy.
[18] S. Spector,et al. Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study. , 2006, The Journal of infectious diseases.
[19] M. Mouroux,et al. Resistance profile and cross‐resistance of HIV‐1 among patients failing a non‐nucleoside reverse transcriptase inhibitor‐containing regimen * , 2001, Journal of medical virology.
[20] F. Bastos,et al. Trends in drug resistance mutations in antiretroviral‐naïve intravenous drug users of Rio de Janeiro , 2006, Journal of medical virology.
[21] D. Pillay,et al. Evolution of Transmitted HIV-1 with Drug-Resistance Mutations in the Absence of Therapy: Effects on Cd4+ T-Cell Count and HIV-1 Rna Load , 2006, Antiviral therapy.
[22] John P. Walsh,et al. Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom , 2007, AIDS.
[23] A. Monforte,et al. Prevalence of HIV-1 primary drug resistance in seroconverters of the ICoNA cohort over the period 1996-2001. , 2004, Journal of acquired immune deficiency syndromes.
[24] JD Lundgren,et al. Updated European Recommendations for the Clinical Use of HIV Drug Resistance Testing , 2004, Antiviral therapy.
[25] M. Peeters,et al. HIV-1 Drug-Resistance Mutations among Newly Diagnosed Patients before Scaling-Up Programmes in Burkina Faso and Cameroon , 2005, Antiviral therapy.
[26] Jonathan AC Sterne,et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study , 2005, The Lancet.